IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
IMMUNIC, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.99+0.02 (+0.29%)
Close on Oct 19, 2026
- Market cap
- $297.17M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Immunic statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Immunic | Industry median |
|---|---|---|
| Market Cap | $95.37M | $166.30M |
| Enterprise Value | -$59.72M | $88.19M |
| PB Ratio | 0.75 | 2.03 |
| P/TBV Ratio | 0.75 | 2.29 |
Income (trailing twelve months)
| Measure | Immunic | Industry median |
|---|---|---|
| Operating Income | -$117.88M | -$21.40M |
| Net Income | -$111.57M | -$22.46M |
| EBITDA | -$117.73M | -$16.91M |
| EPS (Diluted) | -$4.17 | -$0.83 |
Returns
| Measure | Immunic | Industry median |
|---|---|---|
| Return on Equity (ROE) | -138.2% | -53.2% |
| Return on Assets (ROA) | -101.1% | -40.9% |
| Return on Capital Employed (ROCE) | -92.2% | -38.1% |
Balance sheet
| Measure | Immunic | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $155.10M | $61.43M |
| Net Cash (Debt) | $155.10M | $15.35M |
| Net Cash Per Share | $11.37 | $0.66 |
| Equity (Book Value) | $127.58M | $49.09M |
| Book Value Per Share | $9.35 | $1.37 |
| Tangible Book Value | $127.58M | $23.52M |
| Working Capital | $126.57M | $76.81M |
Financial position
| Measure | Immunic | Industry median |
|---|---|---|
| Current Ratio | 5.05 | 3.34 |
| Quick Ratio | 4.96 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Immunic | Industry median |
|---|---|---|
| Operating Cash Flow | -$87.72M | -$12.35M |
| Capital Expenditures | -$329.00K | -$1.08M |
| Free Cash Flow | -$88.05M | -$20.22M |
| FCF Per Share | -$6.45 | -$0.42 |
Efficiency
| Measure | Immunic | Industry median |
|---|---|---|
| Profits Per Employee | -$1.21M | -$703.34K |
| Employee Count | 92 | 74 |
Dividends and yields
| Measure | Immunic | Industry median |
|---|---|---|
| Earnings Yield | -117.0% | -23.3% |
| FCF Yield | -92.3% | -8.72% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Immunic | Industry median |
|---|---|---|
| Shares Outstanding | 13,644,500 | 58,127,000 |
| Shares Change (YoY) | 156.0% | 10.9% |
| Shares Change (QoQ) | 0.17% | 0.54% |
| Shares Held by Institutions | 63.7% | 59.4% |
Scores
| Measure | Immunic | Industry median |
|---|---|---|
| Altman Z-Score | -5.62 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Immunic's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.